Efficacy of Compound Betamethasone Periocular Injection Combined With Oral Mycophenolate Mofetil in Active Thyroid-Associated Ophthalmopathy: A Pilot Study.

Objective: To evaluate the efficacy of combined therapy of compound betamethasone periocular injection and oral mycophenolate mofetil (MMF) in treating active thyroid-associated ophthalmopathy (TAO). Methods: A retrospective study was conducted on 17 patients with active TAO treated with compound betamethasone periocular injection combined with oral MMF from February 2022 to August 2023, involving a total of 31 eyes. Results: In one eye, the Clinical Activity Score (CAS) decreased by less than two points, while in the remaining eyes, the CAS decreased by two points or more. Patients exhibited decreased proptosis, a reduction in average extraocular muscle thickness, and improvement in diplopia in six cases. Subgroup analysis indicated that this regimen showed no significant difference in efficacy for patients treated with radioactive iodine therapy or oral methimazole medication at baseline. Conclusion: Combined therapy of compound betamethasone periocular injection and oral MMF is an effective approach for treating active TAO.